A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, Phase 2 study of TAS-114 administered in combination with
S-1, to investigate the efficacy, safety and tolerability of the TAS-114/S-1 regimen in
patients with advanced or metastatic NSCLC.
The study will be conducted internationally in 2 regions: Asian [Japan] and Western [Europe
and US]. Patients will be randomized into TAS-114/S-1 arm versus S-1 control arm in a 1:1
ratio.